表紙:幹細胞治療の世界市場-2023年~2030年
市場調査レポート
商品コード
1319145

幹細胞治療の世界市場-2023年~2030年

Global Stem Cell Therapy Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
幹細胞治療の世界市場-2023年~2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

幹細胞治療の世界市場は、2022年に58億米ドルに達し、2030年には191億米ドルまで成長すると予測されています。世界の幹細胞治療市場は、予測期間中(2023-2030年)に16.6%のCAGRを示すと予測されています。幹細胞治療は、医療や研究の様々な分野で幅広い応用が期待されています。

幹細胞は、特殊な細胞に分化し、損傷した組織を再生する能力を持つユニークな細胞です。また幹細胞治療は、移植や修復のために機能する組織や臓器を実験室内で作製するプロセスである組織工学においても、重要な役割を果たしています。幹細胞は生体材料や成長因子と混合され、皮膚、軟骨、血管などの人工組織を形成し、損傷した組織や傷ついた組織の代わりとして利用されます。

市場力学

臨床研究数の増加

臨床試験数の増加は、予測期間中に市場が成長するための重要な要因です。臨床研究の目的は、特定の疾患に対する幹細胞治療の有効性を評価することです。研究者は、その治療法の有効性や潜在的な利点を、望ましい結果を達成する能力を調査し、既存の治療法と比較することで分析することができます。

例えば、clinical trials.govによると、2020年4月1日、昆明医科大学延安附属病院は、糖尿病性腎症に対する臍帯間葉系幹細胞治療に関する臨床研究を開始しました。

神経変性疾患の有病率の上昇

神経変性疾患の有病率の上昇も、予測期間中に幹細胞治療市場が成長するための重要な 促進要因です。幹細胞治療は、幹細胞の再生特性により、神経変性疾患の治療アプローチとしての可能性を秘めています。

例えば、Parkinson's Foundationによると、神経変性疾患は世界中で何百万人もの人々に影響を及ぼしています。アルツハイマー病とパーキンソン病は、最も一般的な神経変性疾患です。米国では、620万人もの人々がアルツハイマー病を患っている可能性があり、100万人近くの米国人がパーキンソン病を患っています。

治療選択肢に関する限られた認識

世界の幹細胞治療産業の成長を阻害している主な制約は、治療の選択肢に関する理解不足と胚性幹細胞に対する倫理的懸念です。例えば、国立生物工学情報センター(National Centre for Biotechnology Information)が提供した統計によると、未知の治療法に対する恐怖心や、代替治療法に関する一般市民の理解不足が最大の不安要因となっています。さらに、治療費が高いために導入が進まず、世界的に需要が減少しています。

COVID-19影響分析

COVID-19は幹細胞治療ビジネスに有益な影響を及ぼしました。パンデミックの最中、肺機能障害が死亡の主な原因であったからです。例えば、2020年1月、マイアミ大学の研究者は肺に障害を持つCOVID-19患者に2回の幹細胞注入を行っています。その結果、明らかな副作用は認められず、治療は成功しました。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、世界の幹細胞治療市場に中程度の影響を与えると推定されます。しかし、原材料の輸出入による影響は、予測期間中、世界の幹細胞治療市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 臨床研究数の増加
      • 神経変性疾患の有病率の上昇
    • 抑制要因
      • 治療選択肢に関する認識の限定
    • 機会
      • 市場参入企業による戦略的イニシアティブ
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 同種幹細胞療法
  • 自家幹細胞療法

第8章 細胞源別

  • 脂肪組織由来MSC
  • 骨髄由来MSC
  • 胎盤・臍帯由来MSC
  • その他

第9章 治療用途別

  • 筋骨格系疾患
  • 神経変性疾患
  • 炎症性疾患および自己免疫疾患
  • 心血管疾患
  • その他

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Advanced Cell Technology Inc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Angel Biotechnology
  • Bioheart Inc
  • Brainstorm Cell Therapeutics
  • Caladrius Biosciences
  • Celgene Corporation
  • Cellartis AB
  • CellGenix GmbH
  • Cellular Engineering Technologies Inc
  • Gamida Cell

第14章 付録

目次
Product Code: BT6537

Market Overview

The global stem cell therapy market reached US$ 5.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 19.1 billion by 2030. The global stem cell therapy market is expected to exhibit a CAGR of 16.6% during the forecast period (2023-2030). Stem cell therapy has a wide range of applications in various fields of medicine and research.

Stem cells are unique cells that have the ability to differentiate into specialized cell types and regenerate damaged tissues . Also stem cell therapy plays a crucial role in tissue engineering; process of generating functioning tissues or organs in the laboratory for transplantation or repair. Stem cells are mixed with biomaterials and growth factors to form artificial tissues including skin, cartilage, and blood vessels that may be utilised to replace damaged or wounded tissues.

Market Dynamics

Rise in the Number of Clinical Studies

Rise in the number of clinical studies is the key driver that helps the market to grow during the forecast period. The objective of clinical trials is to assess the efficacy of stem cell therapy for specific medical conditions. Researchers can analyse the efficacy and potential advantages of a therapy by examining its capacity to accomplish desired results and comparing it to existing therapies .

For instance, according to clinical trials. gov, on April 1 2020, Yan'an Affiliated Hospital of Kunming Medical University started a clinical study on Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy which is currently in the early phase 1 where 15 participants have been enrolled for the studies and it is estimated to complete its study by Sep 2024.

Rise in the Prevalence of Neurodegenerative Diseases

Rise in the prevalence of neurodegenerative diseases is also a key driver that helps the stem cell therapy market to grow during the forecast period. Stem cell therapy holds potential as a treatment approach for neurodegenerative diseases due to the regenerative properties of stem cells.

For instance, according to the Parkinson's Foundation Neurodegenerative diseases affect millions of people worldwide. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. In the United States, as many as 6.2 million people may have Alzheimer's disease and Nearly a million Americans are living with Parkinson's disease.

Limited Awareness Regarding Treatment Options

The main constraints impeding the growth of the global stem cell therapy industry are a lack of understanding about treatment choices and ethical concerns about embryonic stem cells. For instance, according to statistics provided by the National Centre for Biotechnology Information, the biggest source of worry is the fear of unknown treatments and a lack of public understanding about treatment alternatives. Furthermore, the high cost of the treatments leads to lesser adoption, resulting in decreasing demand for the product globally.

COVID-19 Impact Analysis

COVID-19 has had a beneficial impact on the stem cell treatment business, as lung dysfunction was the leading cause of mortality during the pandemic. For instance, in January 2020, University of Miami researchers provided two stem cell infusions to COVID-19 patients with lung damage. The results revealed no discernible adverse effects, and the treatment was successful.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global stem cell therapy market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global stem cell therapy market growth over the forecast period.

Segment Analysis

The global stem cell therapy market is segmented based on type, cell source, therapeutic application, end user and region.

The Musculoskeletal Disorders From Therapeutic Application Segment Accounts For 41.3% of Market Share

The musculoskeletal disorders from the therapeutic application segment with around 41.3% are expected to dominate during the forecast period, owing to the prevalence of muscular disease, and the increase in R&D musculoskeletal disorders, which are a large category of illnesses that affect the muscles, bones, joints, tendons, ligaments, and other elements of the musculoskeletal system. These illnesses can cause discomfort, stiffness, reduced range of motion, and other symptoms that interfere with everyday activities.

For instance, in Jan 2023,The National Ethics Committee has approved RegenOrthosport, a BMAC-PRP combination treatment for patients with Musculoskeletal Disorders, using Autologous Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma.

Geographical Analysis

North America Accounted for Approximately 40.6% of the Market Share

North America is estimated to hold about 40.6% of the total market share throughout the forecast period due to the presence of key players engaged in developing stem cell therapies, advanced healthcare infrastructure, extensive R&D, supportive reforms from the healthcare sector, and strong reimbursement policies.

For instance, in June 2023, StemCyte has signed a cooperation agreement with a US immune cell therapy company to supply raw materials for allogeneic-modified cell therapy. The company is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte will supply the necessary cellular raw materials for worldwide allogeneic cell therapy product development.

Competitive Landscape

The major global players in the stem cell therapy include: Advanced Cell Technology Inc, Angel Biotechnology, Bioheart Inc, Brainstorm Cell Therapeutics, Caladrius Biosciences, Celgene Corporation, Cellartis AB, CellGenix GmbH, Cellular Engineering Technologies Inc, Gamida Cell and others.

Why Purchase the Report?

  • To visualize the global stem cell therapy market segmentation based on type, cell source, therapeutic application, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of stem cell therapy market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global stem cell therapy market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Cell Source
  • 3.3. Snippet by Therapeutic Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Number of Clinical Studies
      • 4.1.1.2. Rise in the Prevalence of Neurodegenerative Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Awareness Regarding Treatment Options
    • 4.1.3. Opportunity
      • 4.1.3.1. A Strategic Initiative by Market Players
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Allogeneic Stem Cell Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Autologous Stem Cell Therapy

8. By Cell Source

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 8.1.2. Market Attractiveness Index, By Cell Source
  • 8.2. Adipose Tissue-derived MSCs *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Bone Marrow-derived MSCs
  • 8.4. Placental/Umbilical Cord-derived MSCs
  • 8.5. Others

9. By Therapeutic Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 9.1.2. Market Attractiveness Index, By Therapeutic Application
  • 9.2. Musculoskeletal Disorders *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Neurodegenerative Diseases
  • 9.4. Inflammatory and Autoimmune Disorders
  • 9.5. Cardiovascular diseases
  • 9.6. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Speciality Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Advanced Cell Technology Inc*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Angel Biotechnology
  • 13.3. Bioheart Inc
  • 13.4. Brainstorm Cell Therapeutics
  • 13.5. Caladrius Biosciences
  • 13.6. Celgene Corporation
  • 13.7. Cellartis AB
  • 13.8. CellGenix GmbH
  • 13.9. Cellular Engineering Technologies Inc
  • 13.10. Gamida Cell

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us